RecruitingNot ApplicableNCT07111858

Pavlik Harness Treatment vs Monitoring for Treatment of Developmental Dysplasia of the Hip (DDH) in Babies Diagnosed With Graf Type 2 Hips

Pavlik Harness Treatment Versus Monitoring for Treatment of Graf Type 2b and 2c Hip Developmental Dysplasia of the Hip (DDH)


Sponsor

Maidstone & Tunbridge Wells NHS Trust

Enrollment

70 participants

Start Date

Aug 2, 2023

Study Type

INTERVENTIONAL

Conditions

Summary

Developmental Dysplasia of the Hip (DDH) is thoroughly manageable if treated correctly. While the standard treatment is using a Pavlik harness, there is not enough research regarding those patients who have stable but immature Graf type 2b and 2c hips and whether a harness is needed. At Maidstone and Tunbridge Wells NHS Trust, all babies who present with Graf type 2b and 2c hip dysplasia are treated using a Pavlik harness, which is worn 24 hours a day for up to 12 weeks. Although the harness is usually very comfortable, it can result in stress and anxiety for parents, and may make caregiving activities such as bathing, feeding and carrying more difficult. Our aim is to run a feasibility trial, recruiting babies with type 2b and 2c hip dysplasia, to determine whether there is any difference in a group which is treated with Pavlik harnessing, or whether these hips do in fact mature on their own. We would like to ensure that Pavlik harness treatment is indeed necessary in these groups. Babies randomised to the comparator group with type 2b and 2c hips would be treated using a Pavlik Harness and following the usual protocol with ultrasound scans at 3 weeks, 8 weeks and 12 weeks post start of treatment, and harness duration is determined by the scan at 8 weeks. Babies randomised to the Intervention group would be monitored via ultrasound scans at 3 weeks, 6 weeks, 8 weeks and 12 weeks post diagnosis, and should it be determined that their hips are not maturing spontaneously, they will be placed in a harness immediately, and follow the treatment-group protocol. Since the scans are done so frequently, and their hips are stable, there is no risk to these babies. Babies in both groups would have x-rays at 9 months and 15 months to determine longer-term outcome. The trial will last for 15 months after diagnosis for each patient, and the end-point of the study would be on achieving a 15-month x-ray for the last recruited patient. Patients will be informed of the results of the study.


Eligibility

Min Age: 0 WeeksMax Age: 16 Weeks

Inclusion Criteria1

  • •Infants from birth to 16 weeks with Graf type 2b or 2c hip dysplasia on ultrasound

Exclusion Criteria2

  • associated neuromuscular, genetic or neurological condition which may complicate the course of treatment
  • babies who have unstable hips on clinical examination

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERWatchful waiting with supportive care

Usual care is Pavlik Harness Treatment. Watchful waiting with ongoing ultrasound scans is the intervention in this study to determine whether the hip matures without the use of the Pavlik Harness


Locations(1)

Maidstone and Tunbridge Wells NHS trust

Royal Tunbridge Wells, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07111858